First Analysis Downgrades Adicet Bio (ACET) to Hold

By Austin Angelo

In a report issued on November 14, First Analysis from First Analysis downgraded Adicet Bio (ACETResearch Report) to Hold. The company’s shares closed last Friday at $13.52, close to its 52-week low of $6.02.

Adicet Bio has an analyst consensus of Moderate Buy, with a price target consensus of $25.00, which is a 77.7% upside from current levels. In a report issued on November 15, Guggenheim also downgraded the stock to Hold.

See today’s analyst top recommended stocks >>

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA.